Boehringer Ingelheim GmbH and Eli Lilly and Company could soon be looking forward to further expansion of their blockbuster Jardiance beyond diabetes and heart failure after a late-stage trial of the SGLT2 inhibitor in chronic kidney disease (CKD) patients was stopped early due to "clear positive efficacy."
The EMPA-KIDNEY study, the largest SGLT2 inhibitor trial in CKD to date which started enrolling in 2019, included more than 6,600 adults with mildly to severely reduced eGFR (a measure of kidney function) and with and without diabetes whose disease was attributable to a wide range of underlying causes
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?